PBAC's latest decision on Ciprofloxacin, ear drops: Recommended with restriction (2006). Considered for Treatment of chronic suppurative otitis media (CSOM) in an Aboriginal and Torres Strait Islander person aged one year and older.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
Aboriginal and Torres Strait Islander children under 15 years with CSOM
Therapy area
Other
Line of therapy
Not applicable
Evidence base
RCT, Registry, Cost-minimisation
Primary endpoint
Clinical cure of discharge at 1-2 weeks
Key trials
Couzos et al. 2003, MacFayden (2006), MacFayden (2005)
Comparator
Sofradex (dexamethasone with framycetin sulfate and gramicidin)
Economic model
CUA
Eligible patients/year
100,000
ICER note
Cost-minimisation analysis: incremental cost-effectiveness ratios stated as $10.30 saved per week of earlier resolution (rural) and $23.40 saved per week of earlier resolution (urban). No QALY-based ICER calculated.